Erythropoietin Drugs Market PPT: Growth, Outlook, Demand, Keyplayer Analysis and Opportunity 2023-28

1
Global Erythropoietin Drugs Market Research and
Forecast Report 2023-2028




Author Elena Anderson, Marketing Manager
IMARC Group
Copyright IMARC Service Pvt Ltd. All Rights
Reserved
2019 IMARC All Rights Reserved
2
About IMARC Group
Report Description
The International Market Analysis Research and
Consulting Group is a leading adviser on
management strategy and market research
worldwide. We partner with clients in all sectors
and regions to identify their highest-value
opportunities, address their most critical
challenges, and transform their
businesses. IMARCs information products include
major market, scientific, economic and
technological developments for business leaders
in pharmaceutical, industrial, and high
technology organizations. Market forecasts and
industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel
and tourism, nanotechnology and novel processing
methods are at the top of the companys
expertise. IMARCs tailored approach combines
unfathomable insight into the dynamics of
companies and markets with close cooperation at
all levels of the client organization. This
ensures that our clients achieve unmatchable
competitive advantage, build more proficient
organizations, and secure lasting results.
3
Report Description and Highlights
Report Description
Global Erythropoietin Drugs Market Research
Report The latest report by IMARC, titled
Erythropoietin Drugs Market Global Industry
Trends, Share, Size, Growth, Opportunity and
Forecast 2023-2028 " the global erythropoietin
drugs market size reached US 10.4 Billion in
2022. Erythropoietin (EPO) is a hormone
produced naturally by kidneys to stimulate the
production of red blood cells (RBCs) in the body.
Its deficiency or excess leads to severe medical
conditions, such as low hemoglobin levels and
kidney diseases. EPO drugs, also known as
haematopoietin, are injectable drugs used to cure
anemia and increase RBC production. They are
widely used to treat anemic conditions caused by
chronic renal disease, cancer treatment,
myelodysplasia, medicine side effects, and
surgery. They also help reduce infections in
acquired immune deficiency syndrome (AIDS) and
pre-operative blood transfusion. EPO drugs mimic
the naturally occurring erythropoietin and
stimulate the bone marrow to produce more
RBCs. Request Free Sample Report
https//www.imarcgroup.com/erythropoietin-drugs-ma
rket/requestsample
4
Report Description and Highlights
Report Description

Global Erythropoietin Drugs Market Trends The
widespread prevalence of chronic diseases, such
as cancer, AIDS, and kidney problems, is one of
the primary factors driving the market growth.
EPO drugs are widely used to treat anemic
conditions induced by end-stage renal disease
(ESRD), antiretroviral treatments (ART),
chemotherapy, radiotherapy, and other cancer
treatments. In addition to this, rising product
utilization to treat critically ill patients
owing to its anti-ischemic, anti-apoptotic, and
regenerative effects in various tissues, such as
lungs, kidneys, nervous system, pancreas, and
retina, is acting as another growth-inducing
factor. Furthermore, the rapid commercialization
of highly efficient biosimilars, which are easy
to switch, cost-effective, and require less
approval time, is providing an impetus to the
market growth. In line with this, the widespread
product application in chemotherapy cycles, along
with the increasing incidences of end-stage renal
diseases (dialysis), is favoring the market
growth. Additionally, the recent repurposing of
EPO drugs for treating diabetes mellitus (DM) due
to its cytoprotective effect that enhances
cardiac function, reduces fatigue, and improves
cognition in DM patients is positively
influencing the market growth. Moreover, the
implementation of various government initiatives
to incentivize research on chronic diseases
through grants, drug exclusivity, fee waivers,
and tax credits is propelling the market growth.
Other factors, including rising awareness
regarding the benefits of EPO therapeutics, the
increasing geriatric population in need of
surgical procedures, and rising strategic
collaborations among drug manufacturers due to
high return on investment (ROI), are anticipated
to drive the market growth. On account of the
aforementioned factors, the market value is
expected to reach US 14.5 Billion by 2028,
exhibiting a CAGR of 5.65 during
2023-2028. Looking forward, the market value is
projected to reach a strong growth during the
forecast period (2023-2028).
5
Report Description and Highlights
Report Description
Market Summary Drug Class Insights B
iologics Biosimilars Product Type Insig
hts Epoetin-alfa Epoetin-beta
Darbepoetin-alfa
Others Application Insights Hematology
Kidney Disorder Cancer
Others End-User Insights

6
Report Description and Highlights
Report Description
Hospitals Homecare S
pecialty Clinics Others Regional Insigh
ts North America Unit
ed States Canada Asia-
Pacific China
Japan India So
uth Korea Australia
Indonesia Others
Europe Germany
France

7
Report Description and Highlights
Report Description
United Kingdom
Italy Spain
Russia Others
Latin America Brazil
Mexico Others
Middle East and Africa

8
Report Description and Highlights
Report Description

• Competitive Landscape with Key Players
• Amgen Inc
• Biocon Limited Dr. Reddys Laboratories Ltd. F. Ho
  ffmann-La Roche AG Intas Pharmaceuticals Ltd. John
  son Johnson LG Chem Ltd. Pfizer Inc. Sun Pharmac
  eutical Industries Limited Teva Pharmaceutical Ind
  ustries Ltd.
• View Full Report with TOC List of Figure
  https//www.imarcgroup.com/erythropoietin-drugs-ma
  rket

9
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
10
Partial List of Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
A partial List of our Clients
11
Report Description and Highlights
Report Description

2019 IMARC All Rights Reserved This
Publication and all its contents unless
otherwise mentioned are copyrighted in the name
of International Market Analysis Research and
Consulting (IMARC). No part of this publication
may be reproduced, repackaged, redistributed or
resold in whole or in any part. The publication
may also not be used in any form or by and means
graphic electronic or mechanical, including
photocopying, recording, taping or by information
storage or retrieval, or by any other form,
without the express consent of International
Market Analysis Research and Consulting
(IMARC). Disclaimer All contents and data of
this publication, including forecasts, data
analysis and opinion have been based on
information and sources believed to be accurate
and reliable at the time of publishing.
International Market Analysis Research and
Consulting makes no representation of warranty of
any kind as to the accuracy or completeness of
any Information provided. IMARC accepts no
liability whatsoever for any loss or damage
resulting from opinion, errors or inaccuracies if
any found this publication. IMARC, IMARC Group
and Global Therapy Insight Series are registered
trademarks of International Market Analysis
Research and Consulting. All other trademarks
used in this publication are registered
trademarks of their respective companies.
12

Contact Us